Attached files

file filename
10-Q - CURRENT REPORT - TherapeuticsMD, Inc.txmd-10q_063020.htm
EX-32.1 - SECTION 1350 CERTIFICATION OF CHIEF EXECUTIVE OFFICER - TherapeuticsMD, Inc.ex32-1.htm
EX-31.2 - CERTIFICATION OF CHIEF FINANCIAL OFFICER - TherapeuticsMD, Inc.ex31-2.htm
EX-31.1 - CERTIFICATION OF CHIEF EXECUTIVE OFFICER - TherapeuticsMD, Inc.ex31-1.htm
EX-10.6 - EMPLOYMENT AGREEMENT, BY AND BETWEEN THERAPEUTICSMD, INC. AND JAMES C. D'ARECCA - TherapeuticsMD, Inc.ex10-6.htm
EX-10.5 - SUBSCRIPTION AGREEMENT, - TherapeuticsMD, Inc.ex10-5.htm
EX-10.4 - AMENDMENT NO. 5 TO FINANCING AGREEMENT, - TherapeuticsMD, Inc.ex10-4.htm
EX-10.3 - AMENDMENT NO. 4 TO FINANCING AGREEMENT - TherapeuticsMD, Inc.ex10-3.htm
EX-10.2 - AMENDMENT NO. 3 TO FINANCING AGREEMENT - TherapeuticsMD, Inc.ex10-2.htm
EX-10.1 - AMENDMENT NO. 2 TO FINANCING AGREEMENT - TherapeuticsMD, Inc.ex10-1.htm
EX-4.1 - FORM OF WARRANT TO PURCHASE COMMON STOCK - TherapeuticsMD, Inc.ex4-1.htm
EX-3.1 - COMPOSITE AMENDED AND RESTATED ARTICLES OF INCORPORATION - TherapeuticsMD, Inc.ex3-1.htm
 

TherapeuticsMD, Inc. 10-Q

 

Exhibit 32.2

 

SECTION 1350 CERTIFICATION OF CHIEF FINANCIAL OFFICER

 

In connection with the quarterly report of TherapeuticsMD, Inc. (the "Company") on Form 10-Q for the quarterly period ended June 30, 2020 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, James C. D’Arecca, Chief Financial Officer of the Company, certify to my best knowledge and belief, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

 

(1)The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m(a) or 78o(d)); and

 

(2)The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

 

August 6, 2020   /s/ James C. D’Arecca
    James C. D’Arecca
    Chief Financial Officer
    (Principal Financial Officer)

 

A signed original of this certification has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

 

49